Synonyms: Aloprim® | BW-56-158 | BW-56158 | Zyloprim®
allopurinol is an approved drug (FDA (1966), EMA (2018))
Compound class:
Synthetic organic
Comment: Marketed formulations may contain (PubChem CID 16051976).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Primarily used to treat hyperuricemia (excess uric acid in blood plasma) and its complications, including chronic gout. A fixed dose combination of allopurinol and the urate transporter inhibitor lesinurad (Duzallo®) was FDA approved in August 2017, for the treatment of gout that is not controlled by allopurinol alone. EMA approval for this combination was granted in 2018. Allopurinol sodium has been granted orphan designation by the EMA for the treatment of perinatal asphyxia. |
External links ![]() |
For extended ADME data see the following: Drugs.com |